SCHEMBL5408196

SCHEMBL5408196

CNc1nc(Nc2ccc(Cl)c(Cl)c2)ncc1NC(=O)N1CCCC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.54
▸ NPC1 O15118 1/20 0.54
▸ RAB9A P51151 1/20 0.54
▸ KMT2A Q03164 1/20 0.54
▸ ALK Q9UM73 3/20 0.49
▸ ROS1 P08922 1/20 0.49
▸ BRD4 O60885 1/20 0.49
▸ LRRK2 Q5S007 6/20 0.48
▸ MET P08581 1/20 0.48
▸ JAK2 O60674 1/20 0.48
▸ HTT P42858 1/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ MAPT P10636 2/20 0.46
▸ ULK1 O75385 1/20 0.44
▸ PDK1 Q15118 1/20 0.44
▸ ULK2 Q8IYT8 1/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ CYP2D6 P10635 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ HDAC3 O15379 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5409983 0.99 MEN1 (0.56) MEN1NPC1RAB9AKMT2AALK
SCHEMBL5410626 0.99 MEN1 (0.56) MEN1NPC1RAB9AKMT2AALK
SCHEMBL5405536 0.92 ALK (0.54) ALKBRD4LRRK2JAK2
SCHEMBL5411594 0.92 BRD4 (0.58) ALKBRD4LRRK2JAK2
SCHEMBL5405395 0.91 LRRK2 (0.51) MEN1NPC1RAB9AKMT2AALK
SCHEMBL5416251 0.91 LRRK2 (0.60) ALKROS1LRRK2JAK2
SCHEMBL5415948 0.84 HDAC3 (0.49) MEN1KMT2AALKROS1BRD4
SCHEMBL5415421 0.83 STK17A (0.48) ALKBRD4LRRK2METJAK2
SCHEMBL5408198 0.83 HDAC3 (0.48) NPC1RAB9AALKBRD4LRRK2
SCHEMBL5418427 0.82 HDAC3 (0.47) BRD4LRRK2JAK2HDAC3HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7166599-B2 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2007-01-23 — — US claimed
US-20050090486-A1 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA KG (DE) 2005-04-28 — — US claimed
US-20030134838-A1 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-07-17 — — US claimed
US-7166599-B2 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2007-01-23 — — US disclosed
US-20050090486-A1 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA KG (DE) 2005-04-28 — — US disclosed
US-20030134838-A1 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-07-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030134838-A1 Trisubstituted pyrimidines APP, PSEN1, BACE1 MEN1 3119/4885NPC1 679/4885RAB9A 1793/4885
US-20050090486-A1 Trisubstituted pyrimidines APP, BACE1, PSEN1 MEN1 2729/4885NPC1 1758/4885RAB9A 1327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback